These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8274343)

  • 1. Nurses' guide to the drug development process and the current regulatory environment.
    Leach EE
    Dermatol Nurs; 1993 Oct; 5(5):351-6. PubMed ID: 8274343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe and effective medical devices--everyone's responsibility.
    Franke KA
    Gastroenterol Nurs; 1992 Apr; 14(5):245-8. PubMed ID: 1581379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The US Food and drug administration: drug information resource for formulary recommendations.
    Marchand HC; Ros BJ; Fine AM; Kremzner ME
    J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A; Lauterio TJ; Davis MW
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New FDA Center May Speed Approval Process.
    Cancer Discov; 2016 Sep; 6(9):OF5. PubMed ID: 27417310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Food and Drug Administration advisory committees and panels: how they are applied to the drug regulatory process.
    Ciociola AA; Karlstadt RG; Pambianco DJ; Woods KL; Ehrenpreis ED;
    Am J Gastroenterol; 2014 Oct; 109(10):1508-12. PubMed ID: 25001252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the FDA's advisory committee process.
    Brass EP; Hiatt WR
    J Clin Pharmacol; 2012 Aug; 52(8):1277-83. PubMed ID: 21908879
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S
    Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Evidence, Public Participation, and the FDA.
    Schwartz JL
    Hastings Cent Rep; 2017 Nov; 47(6):7-8. PubMed ID: 29171057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA's new oncology office.
    Pazdur R
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):612-3. PubMed ID: 16167044
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One hundred years of drug regulation: where do we go from here?
    Woosley RL
    Annu Rev Pharmacol Toxicol; 2013; 53():255-73. PubMed ID: 23072378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.